Previous close | 1.4720 |
Open | 1.4060 |
Bid | 1.3420 x 0 |
Ask | 1.3820 x 0 |
Day's range | 1.4060 - 1.4060 |
52-week range | 0.5770 - 2.1350 |
Volume | |
Avg. volume | 3,158 |
Market cap | 176.814M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.2200 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.75 |
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The Karisma-Endoxifen study, which fully enrolled in November 2023, is a 240-person
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Ato